ADCETRIS Powder for Concentrate for Solution for Infusion
Brentuximab vedotin
50 mg
BAXALTA US Inc.
| Pack size | 1 Vial |
|---|---|
| Dispensing mode | |
| Source | |
| Agent | |
| Retail Price | 13071.30 AED |
Indications
ADCETRIS Powder for Concentrate for Solution for Infusion is used for:
Used in the treatment of Hodgkin lymphoma and systemic anaplastic large cell lymphoma.
Adult Dose
Child Dose
Renal Dose
Administration
Contra Indications
Precautions
Pregnancy-Lactation
Interactions
Adverse Effects
Side effects of Brentuximab vedotin :
Mechanism of Action
Brentuximab vedotin is composed of 3 parts: a chimeric human-murine IgG1 that targets CD30, monomethyl auristatin E (MMAE),which is a microtubule disrupting agent, and a protease-susceptible linker that covalently links the antibody and MMAE. The IgG1 antibody enables brentuximab vedotin to target tumor cells expressing CD30 on their cell surface then brentuximab vedotin gets internalized into the cell. Once inside, the linker is cleaved releasing MMAE which binds disrupts the microtuble network.
Note
ADCETRIS 50 mg Powder for Concentrate for Solution for Infusion manufactured by BAXALTA US Inc.. Its generic name is Brentuximab vedotin. ADCETRIS is availble in Saudi Arabia.
Farmaco SA drug index information on ADCETRIS Powder for Concentrate for Solution for Infusion is not intended for diagnosis, medical advice or treatment; neither intended to be a substitute for the exercise of professional judgment.